SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more
SynCore Biotechnology Co Ltd (4192) - Total Liabilities
Latest total liabilities as of September 2025: NT$14.88 Million TWD
Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has total liabilities worth NT$14.88 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SynCore Biotechnology Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how SynCore Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SynCore Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GFL Limited
NSE:GFLLIMITED
|
India | ₹1.66 Billion |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
Malaysia | RM434.75 Million |
|
Xbrane Biopharma AB
ST:XBRANE
|
Sweden | Skr110.97 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
USA | $3.72 Million |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
India | ₹3.76 Billion |
|
Beyond Air Inc
NASDAQ:XAIR
|
USA | $28.49 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down SynCore Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SynCore Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual total liabilities of SynCore Biotechnology Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$23.11 Million | +8.89% |
| 2023-12-31 | NT$21.23 Million | -88.69% |
| 2022-12-31 | NT$187.64 Million | -50.82% |
| 2021-12-31 | NT$381.52 Million | +7.95% |
| 2020-12-31 | NT$353.41 Million | +132.75% |
| 2019-12-31 | NT$151.84 Million | +54.77% |
| 2018-12-31 | NT$98.11 Million | -21.68% |
| 2017-12-31 | NT$125.28 Million | -15.61% |
| 2016-12-31 | NT$148.46 Million | -19.52% |
| 2015-12-31 | NT$184.46 Million | -- |